Dr. Reddy's Laboratories Limited (RDY) Stock Score, Valuation & Financial Research
Dr. Reddy's Laboratories Limited is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 53/100.
Quick answer for RDY
Dr. Reddy's Laboratories Limited currently has a Wall Street Score of 53/100. The stored market price is $11.9. Its financial score is 35/100. Its valuation score is 83/100. These figures are a research snapshot, not a buy or sell recommendation.
What Dr. Reddy's Laboratories Limited does
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs a
RDY financial snapshot
- Wall Street Score:
- 53/100
- Current price:
- $11.9
- Market capitalization:
- $9.91B
- Revenue:
- $3.44B
- Net income:
- $342.9M
- Free cash flow:
- $331.9M
- Cash:
- $155.7M
- Total debt:
- $783.8M
- EPS:
- 0.56
- P/E ratio:
- 21.3x
- Financial score:
- 35/100
- Valuation score:
- 83/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $331.9M, showing positive cash generation.
- The balance sheet shows $155.7M of cash versus $783.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 83/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 35/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RDY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.